

Corrigendum

**Corrigendum to “Synthesis, characterization and evaluation of  
pro-drugs of VLA-4 antagonists”  
[Bioorg. Med. Chem. Lett. 14 (2004) 1651]**

D. M. Hurynd,<sup>a,\*</sup> Susan Ashwell,<sup>a,†</sup> Reinhardt Baudy,<sup>a</sup> Darren B. Dressen,<sup>b</sup>  
William Gallaway,<sup>a</sup> Francine S. Grant,<sup>b,‡</sup> Andrei Konradi,<sup>b</sup> Robert W. Ley,<sup>c</sup>  
Susan Petusky,<sup>a</sup> Michael A. Pleiss,<sup>b</sup> Dimitri Sarantakis,<sup>a</sup> Christopher M. Semko,<sup>b</sup>  
Mary M. Sherman,<sup>a,§</sup> Cesar Tio<sup>d</sup> and Lu Zhang<sup>a</sup>

<sup>a</sup>Chemical & Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543, USA

<sup>b</sup>Elan Pharmaceuticals, 800 GatewayBoulevard, South San Francisco, CA 94080, USA

<sup>c</sup>Department of Pharmaceutical Sciences, Unit 50, Wyeth Research, 156 Fareham Road, Gosport, UK

<sup>d</sup>Department of Drug Safety & Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA

Available online 15 September 2004

The authors regret that the beginning of the first paragraph on p 1652 contains an error. The corrected text should read:

To evaluate its potential to be developed as an oral agent, the physico-chemical properties of **1** were measured. A single  $pK_a^{13}$  was measured at 3.30. The neutral species, which exists at low pH values, exhibits log *P* values in the range of 3–4.<sup>14</sup> These results indicate **1** will be ionized over the critical pH range 5–8, and predict it will be poorly absorbed.<sup>15</sup>

DOI of original article: 10.1016/j.bmcl.2004.01.062

\* Corresponding author. Tel.: +1-732-274-4025; fax: +1-732-274-4129; e-mail: [hurynd@wyeth.com](mailto:hurynd@wyeth.com)

† Current Address: AstraZeneca Pharmaceuticals LP, 35 Gatehouse Drive, Waltham, MA 02451, USA.

‡ Current Address: Icos Pharmaceuticals, 2023 120th Avenue NE, Bellevue, WA 98005, USA.

§ Current Address: MPI Research, 54943 N. Main Street, Mattawan, MI 49071, USA.